|
A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya®(somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice
|
Ongoing
|
Sogroya®
|
4
|
NN8640-451
|
My Clinic (Jeddah),King Fahad Medical City (Riyadh),Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh)
|
|
Low INR to Minimize bleeding with mechanical valves Trial (LIMIT)
|
Ongoing
|
WARFARIN SODIUM
|
3
|
2231351
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Randomized, Single Oral Dose, Open Label, Two Sequence, Two Treatment, Four Periods, Full Replicate Crossover Study to Determine the Bioequivalence of Azacitidine 300 mg Film Coated Tablets Versus Onureg® 300 mg Film Coated Tablets For Adult Patients with Acute Myeloid Leukaemia (AML) under Fasting Conditions
|
Ongoing
|
Azacitidine 300 mg Film- Coated Tablets
|
BE
|
HIK-AZA-2023-01
|
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam)
|
|
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease
|
Ongoing
|
Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001)
|
3
|
VX21-CTX001-161
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD
|
Ongoing
|
BI 456906
|
3
|
1404-0040
|
King Faisal Specialist Hospital and Research Center (Riyadh) , King Fahad Specialist Hospital (Dammam), King Abdulaziz University Hospital (Jeddah),King Saud Medical City (Riyadh)
|
|
Open-label, long-term safety and efficacy study of Mim8 in participants with haemophilia A with or without inhibitors
|
Ongoing
|
NNC0365-3769 B (Mim8)
|
3
|
NN7769-4532
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell Carcinoma (OPERA)
|
Ongoing
|
Tyrosine Kinase inhibitors and Immunotherapy
|
4
|
OPERA2020
|
King Faisal Specialist Hospital and Research Center (Jeddah)
|
|
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
|
Ongoing
|
Upadacitinib (Rinvoq)
|
3
|
M23-698
|
King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah)
|
|
A Phase 3, single-arm, multicenter, multinational, open label,one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX
|
Ongoing
|
Fitusiran
|
3
|
EFC17574
|
King Faisal Specialist Hospital and Research Center (Riyadh) , King Abdulaziz University Hospital (Jeddah)
|
|
A single arm, multicentre observational study to evaluate effectiveness of pegcetacoplan under real world conditions in patients with paroxysmal nocturnal hemoglobinuria (PNH) COMPLETE
|
Ongoing
|
pegcetacoplan (ASPAVELI)
|
4
|
Sobi.PEGCE
|
King Faisal Specialist Hospital and Research Center (Jeddah),King Faisal Specialist Hospital and Research Center (Riyadh),King Faisal Specialist Hospital and Research Center (Madinah)
|
